Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis

References

• Campbell JD, Ghushchyan V, McQueen RB, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord 2014;3:227–36
   PubMed Web of Science ®Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014;83:1022–4
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703–12
   PubMed Web of Science ®Google Scholar
• Kornblith AB, La Rocca NG, Baum HM. Employment in individuals with multiple sclerosis. Int J Rehabil Res 1986;9:155–65
   PubMed Web of Science ®Google Scholar
• Bøe Lunde HM, Telstad W, Grytten N, et al. Employment among patients with multiple sclerosis-a population study. PLoS One 2014;9:e103317
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009;27:681–91
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. The cost of disability and medically-related absenteeism among employees with multiple sclerosis. Value Health 2008;11:A143
   Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255–66
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910
   PubMed Web of Science ®Google Scholar
• Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;71:766–73
   PubMed Web of Science ®Google Scholar
• Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 2009;15:1175–82
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin 2009;25:869–77
   PubMed Web of Science ®Google Scholar
• Riñon A, Buch M, Holley D, et al. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence 2011;5:629–43
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. WHO/MNC/03.01. 2003. http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html. Accessed September 23, 2014
   Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19:S24–41
   PubMed Web of Science ®Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89–100
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51–61
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ 2012;15:1–9
   Google Scholar
• Parise H, Laliberté F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers. J Neurol Sci 2013;330:71–7
   PubMed Web of Science ®Google Scholar
• Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075–9
   PubMed Web of Science ®Google Scholar
• Bergvall N, Patrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ 2014;17:696–707
   PubMedGoogle Scholar
• Nau D. Proportion of Days Covered (PDC) as a preferred method of measuring medication adherence. Pharmacy Quality Alliance. http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf. Accessed January 13, 2014
   Google Scholar
• Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers Seasonally Adjusted: CUSR0000SA0 U.S. City Average All Items and CUSR0000SAM U.S. City Average Medical Care. http://data.bls.gov/pdq/querytool.jsp?survey=cu. Accessed April 3, 2015
   Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1–9
   PubMed Web of Science ®Google Scholar
• Turner AP, Kivlahan DR, Sloan AP, et al. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler 2007;13:1146–52
   PubMed Web of Science ®Google Scholar
• Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011;5:73–84
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663–74
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Beren IA, Rajagopalan K, et al. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633–40
   PubMedGoogle Scholar
• Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306–9
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:67–77
   Google Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 2013;13:138
   PubMed Web of Science ®Google Scholar
• Stewart TM, Tran ZV. Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions. Int J MS Care 2012;14:46–53
   PubMedGoogle Scholar
• Osterber L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar